Edwards Lifesciences Corporation reported fourth quarter (Q4) sales of USD 1.57 billion, representing an increase of 13.3%. Transcatheter aortic valve replacement (TAVR) sales for Q4 were USD 1.16 billion, up 12.0%. Transcatheter mitral and tricuspid therapies (TMTT) sales in the same period grew more than 40% to USD 156 million. Net income attributable to shareholders for Q4 was USD 91.2 million. Basic earnings per share from continuing operations was USD 0.11, and diluted earnings per share from continuing operations was also USD 0.11. Adjusted earnings per share for Q4 was USD 0.58. For the full year (FY) 2025, sales grew by 11.5%. The company reported increased confidence in achieving its 2026 constant currency sales growth guidance of 8 to 10% and in reaching adjusted earnings per share of USD 2.90 to USD 3.05. The 2026 revenue outlook includes TMTT sales projected to grow 35 to 45% to between USD 740 million and USD 780 million. Edwards Lifesciences ended 2025 with cash and cash equivalents of approximately USD 3.00 billion and total debt of around USD 600 million. The company expects its full-year 2026 operating profit margin to be at the high end of its original guidance range of 28 to 29%. For the first quarter of 2026, Edwards Lifesciences projects total sales between USD 1.55 billion and USD 1.63 billion and adjusted earnings per share of USD 0.70 to USD 0.76.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210513744) on February 10, 2026, and is solely responsible for the information contained therein.